TLDR The 7.1% withdrawal rate was in the oral finasteride group, not the topical one.
In the article by B.M. Piraccini et al., there was an error in the "Safety assessment" subsection. The incorrect sentence stated that withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the topical finasteride group. The corrected sentence clarifies that the 7.1% withdrawal rate was actually in the oral finasteride group.
11 citations,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” Topical finasteride is an effective and safer treatment for male hair loss.
[object Object]
1 citations,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
[object Object] 4 citations,
December 2020 in “Giornale italiano di dermatologia e venereologia” Italian guidelines recommend using trichoscopy for diagnosis and treatments like minoxidil for hair loss.
February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”